Nasus Pharma (NSRX) announced that it recently received a No-Objection Letter from Health Canada, the country’s primary regulatory authority for drugs and medical products, for the Company’s planned Phase 2 clinical study of NS002, its investigational intranasal epinephrine powder formulation for the treatment of anaphylaxis. The Health Canada authorization marks an important regulatory milestone in the NS002 development program. This clearance confirms the acceptability of the proposed trial design, supporting safety data, and manufacturing information, and enables Nasus to advance towards its planned Phase 2 clinical study.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NSRX:
- Nasus Pharma Updates Corporate Presentation
- Nasus Pharma participates in conference call hosted by Citizens JMP
- Nasus Pharma’s Innovative Approach to Anaphylaxis Treatment: A Clinical Study Update
- Nasus Pharma Expands Collaboration with Aptar for Intranasal Epinephrine Program
- Nasus Pharma announces expanded agreement to support NS002